| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8580900 | Primary Care Diabetes | 2016 | 7 Pages |
Abstract
Under real-life settings, vildagliptin as add-on to SU monotherapy showed better glycaemic response without tolerability issues compared with other OADs.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
K.M. Prasanna Kumar, U. Phadke, H. Brath, A. Gawai, P.M. Paldánius, C. Mathieu,